Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO ...
CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the pharmacy benefit manager Caremark, will not add Yeztugo, Gilead’s (NASDAQ:GILD) newly approved HIV PrEP, to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback